Oncology / Hematology | Physician's Weekly
Advertisement

Oncology / Hematology

CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis

Jan 28, 2022

FRIDAY, Jan. 28, 2022 (HealthDay News) -- For patients with rheumatoid arthritis aged 50 years or older with one or more additional cardiovascular risk factors, increased risks for major adverse cardi...

Young Have Greatest Burden of Distant Colorectal Adenocarcinoma

Jan 28, 2022

THURSDAY, Jan. 27, 2022 (HealthDay News) -- The youngest adults have the greatest burden of distant-stage early-onset colorectal adenocarcinoma, according to a study published online Jan. 26 in Cancer...

Screening Nonsmokers May Up Lung Cancer Overdiagnosis, Spurious Survival Rates

Jan 27, 2022

WEDNESDAY, Jan. 26, 2022 (HealthDay News) -- Low-dose computed tomography (LDCT) screening of mostly nonsmoking Asian women is associated with considerable early-stage lung cancer overdiagnosis, accor...

Prognostic Index May ID CLL Patients Who Will Not Need Treatment

Jan 27, 2022

TUESDAY, Jan. 25, 2022 (HealthDay News) -- A composite score can identify patients with chronic lymphocytic leukemia (CLL) with very low risk for requiring treatment, according to a study published on...

Blood Biomarkers May Help Assess Need for Lung Cancer Screening

Jan 27, 2022

TUESDAY, Jan. 25, 2022 (HealthDay News) -- A four-marker protein panel (4MP), including the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fra...

Blood Biomarkers May Help Assess Need for Lung Cancer Screening

Jan 27, 2022

TUESDAY, Jan. 25, 2022 (HealthDay News) -- A four-marker protein panel (4MP), including the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fra...

Screening Nonsmokers May Up Lung Cancer Diagnosis, Survival Rates

Jan 27, 2022

WEDNESDAY, Jan. 26, 2022 (HealthDay News) -- Low-dose computed tomography (LDCT) screening of mostly nonsmoking Asian women is associated with considerable early-stage lung cancer overdiagnosis, accor...

Black Patients More Likely to Have Negative Descriptors in Notes

Jan 25, 2022

MONDAY, Jan. 24, 2022 (HealthDay News) -- Black patients are more likely than White patients to have at least one negative descriptor in the history and physical notes of their electronic health recor...

Overall, Night Shift Work Not Tied to Higher Lymphoma Risk

Jan 25, 2022

MONDAY, Jan. 24, 2022 (HealthDay News) -- Night shift work may increase the risk for chronic lymphocytic leukemia (CLL), according to a study published online Jan. 13 in Occupational & Environmental M...

Adding Immunotherapy to Chemo Ups Survival in Advanced Biliary Tract Cancer

Jan 24, 2022

MONDAY, Jan. 24, 2022 (HealthDay News) -- Adding the immunotherapeutic agent durvalumab to standard chemotherapy improves survival in advanced biliary tract cancer, according to a study presented at t...

Combo Immunotherapy Ups Survival in Advanced Liver Cancer

Jan 24, 2022

MONDAY, Jan. 24, 2022 (HealthDay News) -- STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as first-line therapy for unresectable hepatocellular carcinoma (uHCC), according to a st...

Risk for Cancer Increased After VTE for Patients With Psoriasis

Jan 24, 2022

MONDAY, Jan. 24, 2022 (HealthDay News) -- For patients with psoriasis, the risk for cancer is increased at the time of or after venous thromboembolism (VTE), according to a research letter published o...

Frailty Mars Outcomes After aHSCT in Lymphoid Malignancies

Jan 24, 2022

MONDAY, Jan. 24, 2022 (HealthDay News) -- For patients with lymphoid malignancies undergoing autologous hematopoietic stem cell transplantation (aHSCT), frailty is associated with worse hospital outco...

Cost Analysis of Using Prognostic Test in Decision-Making of Patients with Lung Cancer

Jan 24, 2022

Researchers have developed a prognostic test to direct adjuvant chemotherapy (ACT) decision in early-stage non-small cell lung cancer (NSCLC) adenocarcinomas. The purpose of their study was to weigh u...

A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.

Jan 24, 2022

. Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare aggressive renal malignancy associated with hereditary leiomyomatosis and RCC syndrome (HLRCC). Tumors exhibiting heterogeneous...

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

Jan 24, 2022

Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer. This individual patient da...

Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.

Jan 24, 2022

During disease progression from primary towards metastatic prostate cancer (PCa), and in particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the cancer clones, alteri...

Real-time monitoring of single-cell secretion with a high-throughput nanoplasmonic microarray.

Jan 24, 2022

Proteins secreted by cells play significant roles in mediating many physiological, developmental, and pathological processes due to their functions in intra/intercellular communication and signaling. ...

Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.

Jan 24, 2022

Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 can achieve impressive clinical remission rates in the treatment of B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leu...

Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment.

Jan 24, 2022

Histone lysine specific demethylase 1 (LSD1) is a promising new therapeutic target for cancer therapy. Following the work on the discovery of natural LSD1 inhibitor higenamine, we herein performed fur...